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Summary Wnt proteins (Wnts) are palmitoylated and glycosylated ligands that play a central
role in the early development of organs and tissues. The discovery that loss-of-function mutations
in low density lipoprotein receptor-related protein 5 (LRP5), a Wnt co-receptor, led to low bone
mass in humans revealed the possible role of Wnt signaling in the regulation of bone remodeling.
Many findings obtained from detailed analyses of mice having mutations of Wnt signaling
molecules have confirmed that Wnt signaling has potential roles in bone remodeling in both
physiological and pathological conditions. There are two pathways of Wnt signaling: b-catenin-
dependent canonical and -independent non-canonical pathways. Wnts act on osteoblast pre-
cursor cells and promote their differentiation into mature osteoblasts through the b-catenin-
dependent canonical pathway. In addition, Wnts suppress bone resorption by regulating the
receptor activator of NF-kB ligand (RANKL)/osteoprotegerin (OPG) ratio through the same
pathway in mature osteoblasts. In contrast, recent studies have shown that the activation of
the b-catenin-independent non-canonical pathway enhances the RANKL-induced osteoclast
formation in mouse macrophage cultures. These results indicate that Wnt-mediated signals
are involved in several aspects of bone formation and bone resorption. This reviewwill summarize
the current knowledge of the roles of Wnt signaling in bone formation and resorption.
# 2008 Japanese Association for Dental Science. Published by Elsevier Ireland. All rights reserved.1. Introduction
Bone remodeling is a dynamic process orchestrated by bone-
forming osteoblasts and bone-resorbing osteoclasts. Osteo-
blasts are mononuclear cells responsible for bone formation.
Osteoblasts are differentiated from mesenchymal progenitor
cells at sites of membranous bone formation and endochon-* Corresponding author. Tel.: +81 263 51 2238; fax: +81 263 51 2223.
E-mail address: ykoba@po.mdu.ac.jp (Y. Kobayashi).
1882-7616/$ — see front matter # 2008 Japanese Association for Denta
doi:10.1016/j.jdsr.2007.11.002dral bone formation [1,2]. Osteoclasts are multinuclear cells
responsible for bone resorption. Osteoclasts are derived from
monocyte-macrophage lineage cells. Besides their roles in
bone formation, osteoblasts regulate osteoclastic bone
resorption [3]. Osteoblasts express two cytokines required
for osteoclast differentiation and function, macrophage-col-
ony stimulating factor (M-CSF) and receptor activator of NF-
kB ligand (RANKL) [4]. M-CSF is constitutively expressed in
osteoblasts, whereas RANKL is inducibly expressed in osteo-
blasts in response to bone resorption-stimulating factors such
as parathyroid hormone (PTH) and 1a,25-dihydroxyvitaminl Science. Published by Elsevier Ireland. All rights reserved.
Wnt signaling in bone 77D3 [1a,25(OH)2D3]. Osteoblasts also express a negative reg-
ulator of bone resorption, osteoprotegerin (OPG), which
inhibits the interaction between RANK and RANKL by acting
as a decoy receptor of RANKL [5]. Wnt proteins (Wnts) play a
central role in the early development of organs and tissues
[6]. Recent studies have established that Wnt-mediated
signals have important roles in bone remodeling in both
physiological and pathological conditions. In this review,
we will introduce the molecules involved in the Wnt signaling
pathway in detail, and focus on the role of Wnt signaling in
bone formation and bone resorption.
2. Molecules involved in Wnt signaling
2.1. Ligands
Wnts are a family of 19 molecules in mammals, each con-
sisting of 350—400 amino acids [7]. Wnts possess 22—24
conserved cysteine residues, and show 20—80% amino acid
identity among the family members. Xenopus Wnts (XWnts)
are divided into two classes: the canonical Wnt class (e.g.,
XWnt1, XWnt3a and XWnt8) and the non-canonical Wnt class
(e.g., XWnt4, XWnt5a, and XWnt11) [7]. However, this clas-
sification of XWnts cannot be applied in the other species.
Non-canonical Wnt5a activated the canonical pathway inFigure 1 Structural characteristics of Wnt-related molecules. Lig
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Kremen 1.HEK293 cells co-expressing frizzled 4 and LRP5 [8]. This
finding suggests that combination of frizzleds and their co-
receptors determines the Wnt signaling pathway to be acti-
vated.
2.2. Receptors
Frizzled is a seven transmembrane receptor of Wnts. The
Frizzled family consists of 10 members in mammals with
wide-ranged in the size from 500 to 700 amino acids [9].
There is a cysteine-rich domain (CRD) in the amino terminal
extracellular region in Frizzled. The CRD is necessary for
binding of Wnts. The KTXXXWmotif located after the seventh
hydrophobic domain is highly conserved in Frizzled members
and is essential for activation of the canonical Wnt pathway
(Fig. 1).
2.3. Co-receptors
LRP5 and LRP6 are transmembrane proteins with 1615 and
1613 amino acids, respectively. Both proteins belong to the
LDLR family. Unlike other LDLR family members, LRPs 5 and 6
act as co-receptors of Frizzleds to induce the canonical Wnt
pathway. The amino-terminal extracellular domain of LRP is
composed of four YWTD repeat domains, four epidermalands: Wnts consist of 350—400 amino acid residues with 22—24
amino acids. The CRD in Frizzled is necessary for binding of Wnt.
is essential for activation of the canonical Wnt pathway. Co-
brane proteins, respectively. The amino-terminal extracellular
-like domains and an LDLR-like ligand-binding domain. The first
1 and ROR2 consist of 882 and 909 amino acids, respectively. Wnt
eins harbors a TKD and a PRD. Antagonists/agonists: SFRPs consist
Ks consist of 206—366 amino acids and contain two characteristic
hibitory effect of DKK1 requires another interaction of DKK1 with
78 Y. Kobayashi et al.growth factor (EGF)-like domains and an LDLR-like domain
(LDLRLD) [10]. A single YWTD repeat domain consists of six
tandem YWTD sequences. The first YWPD repeat domain
binds to Wnt, and the third one binds to Dickkopf (DKK).
The binding of DKK to LRP interferes with the binding of Wnt
and LRP and inhibits the canonical Wnt signals.
Receptor tyrosine kinase orphan receptor (ROR)1 and ROR2
belong to the tyrosine kinase (Trk) receptor family [11]. These
proteins were first isolated as homologues of Trk neurotrophin
receptors. Ror1 and Ror2 genes encode 882 and 909 amino
acids, respectively. RORs are expressed in a variety of organs,
including skeletal tissues. The extracellular region of ROR
consists of an immunoglobulin-like domain (IgLD), a CRD and
a kringle domain (KD). Wnt proteins bind to the CRD of ROR.
The intracellular region of ROR harbors a tyrosine kinase
domain (TKD) and a proline-rich domain (PRD).
2.4. Antagonists and agonists
Secreted frizzled-related proteins (SFRPs) are a family ofWnt
antagonists. This family consists of fivemembers with ranging
in size from 286 to 325 amino acids. SFRP contains a CRD in
the amino-terminal region and a netrin-like domain (NTR) in
the carboxy-terminal region [12]. SFRP directly binds to Wnt
and inhibits the interaction between Wnt and Frizzled. The
CRD of SFRP is the binding site of Wnt. The DKK family is
composed of four members with 206—366 amino acids.
Among DKK family members, DKK1 and DKK4 inhibit Wnt
signaling pathways. DKK contains two characteristic CRDs
(CRD1 and CRD2). CRD2 is highly conserved among all mem-
bers of this family. Unlike SFRP, DKK1 binds to LRP 6 through
CRD1. The binding of DKK1 to LRP6 inhibits the activation of
the canonical Wnt pathway (Fig. 2) [13].Figure 2 Wnt signaling pathways. In the absence of Wnts, GSK-3b
scaffolds for GSK-3b and b-catenin. Phosphorylated b-catenin is degr
signaling: (A) b-catenin-dependent canonical pathway and (B) b-cate
to the receptor complex of Frizzled and LRP5 or LRP6, inhibit GSK-3b
catenin translocates into the nucleus and together with TCF/LEF ind
bind to the receptor complex of Frizzled and ROR1/2. This binding a
JNK-dependent signals. Non-canonical Wnts also activate protein kin
also can activate the non-canonical pathway.2.5. Others
Kremen proteins are single-pass transmembrane receptors
for DKK1. The interaction of DKK1 with Kremen 1 is required
for the inhibitory effect of DKK1 on the canonical Wnt path-
way. DKK1, LRP6 and Kremen form a ternary complex. The
formation of the ternary complex promotes endocytosis of
the complex and the removal of LRPs from the plasma
membrane, resulting in the shutdown of the canonical Wnt
pathway [13]. There are three other proteins named Wnt
inhibitory factor-1, Wnt modulator in surface ectoderm and
Cerberus, which inhibit the Wnt signaling pathways. The
roles of those proteins in Wnt signaling are described in more
detail in a review article [11].
3. Wnt signaling pathways
Wnt binds to two distinct receptor complexes: a complex of
Frizzled and LRP5/6 and another complex of Frizzled and
RORs. The binding of Wnt to the receptors activate two
classes of signaling pathways: a b-catenin-mediated canoni-
cal pathway and a b-catenin-independent non-canonical
pathway [6]. In the absence of Wnt signaling, glycogen
synthase kinase-3b (GSK-3b) phosphorylates b-catenin in
the target cells (Fig. 2). Adenomatous polyposis coli (APC)
and axin act as scaffold proteins allowing the association of
GSK-3b with b-catenin. Phosphorylated b-catenin is
degraded through the ubiquitin-proteosome pathway. Wnt1
class ligands such as Wnt1 and Wnt3a activate the canonical
pathway through the formation of a complex of Wnt,
Frizzled, and LRP5 or LRP6. This complex in turn promotes
the phosphorylation of GSK-3b, which inhibits the kinase
activity of GSK-3b. Inactivation of GSK-3b induces the accu-phosphorylates b-catenin in the target cells. APC and axin act as
aded by ubiquitin/proteosomes. There are two pathways for Wnt
nin-independent non-canonical pathway. (A) Canonical Wnts bind
and promote the accumulation of b-catenin. The accumulated b-
uces the expression of Wnt target genes. (B) Non-canonical Wnts
ctivates the planar cell polarity pathway through RhoA, Rac and
ase C (PKC)- and calcineurin-dependent signals. Canonical Wnts
Figure 3 Roles of Wnt signaling in bone remodeling. (A) Cano-
nical Wnt signaling promotes differentiation of osteoblast pre-
cursors into mature osteoblasts, which in turn increases bone
formation. The canonical Wnt signaling also induces the up-
regulation of OPG expression and down-regulation of RANKL
expression in osteoblasts, resulting in the inhibition of bone
resorption. Thus, activation of the canonical Wnt pathway leads
to a net increase in bone mass. On the other hand, Wnt5a-
induced activation of the non-canonical pathway in osteoclast
precursors enhances RANKL-induced osteoclast formation. Non-
canonical Wnts also induced the production of inflammatory
cytokines in synovial cells from RA patients. The non-canonical
Wnt signaling promotes bone destruction in inflammatory dis-
eases. (B) Phenotypes of bone in mice lacking Wnt signaling
molecules.
Wnt signaling in bone 79mulation of b-catenin in the target cells, followed by trans-
location of accumulated b-catenin into the nucleus. The
nuclear b-catenin, together with transcription factors, T-cell
factor/lymphoid enhancer factor (TCF/LEF) family members,
induces the expression of the Wnt target genes (Fig. 2). In the
other pathway,Wnt5a binds to a receptor complex of Frizzled
and ROR1/2 (Fig. 2). The binding of Wnt5a to a receptor
complex activates heterotrimeric G proteins, which increase
intracellular calcium via protein kinase C (PKC)–—and calci-
neurin-dependent mechanisms [14—17]. Wnt5a also acti-
vates the planar cell polarity pathway through Rho- and
Rac/c-Jun amino-terminal kinase (JNK)-dependent signals
[18—21].
4. Role of Wnt signaling in bone formation
Loss-of-function mutations in human LRP5 are associated
with osteoporosis-pseudoglioma syndrome, which is charac-
terized by severe juvenile-onset osteopenia, and congenital
or infant-onset blindness [22]. In contrast, mutations in the
amino-terminal region of LRP5 (e.g., G171V) that reduce the
binding affinity of LRP5 to DKK1 lead to high bone mass
[23,24]. Recently, a loss-of-function mutation in human
LRP6 was discovered in a family suffering from the early-
onset of coronary artery disease [25]. This mutation also
leads to low bone mass in the patients. The bone phenotypes
found in humans with LRP5 and LRP6mutations are largely in
accord with the data from animal models. Lrp5/mice show
a low bonemass phenotype [26]. The low bonemass in Lrp5/
mice is further exacerbated by loss of a single allele of Lrp6
[27]. The ringelschwantz (rs) mutant mouse has a naturally
occurring arginine-to-tryptophan mutation at amino acid 886
in Lrp6 that attenuates efficient signaling via the canonical
Wnt pathway [28]. In addition to defects of the axial skele-
ton, digits and neural tube formation, rs/rs mice show a delay
in the formation of ossification centers during embryogenesis
and decreased bone mass. These findings suggest that the
canonical Wnt pathway mediated through LRP5 and LRP6
influences bonemass. Onemechanismwhereby the canonical
Wnt pathway increases bone mass is believed to be the
stimulation of osteoblastogenesis. Bone analysis of Lrp5/
mice revealed that the proliferation of osteoblast progeni-
tors was significantly reduced in those mice [26]. Adminis-
tration of LiCl, an inhibitor of GSK-3b, for 4 weeks
dramatically increased bone formation and the number of
osteoblasts in mice [29]. Similar results were also observed in
Lrp5/ mice given LiCl [29]. These findings suggest that
activation of the canonical Wnt pathway leads to an increase
in bone mass (Fig. 3).
Effects of Wnt antagonists on bone mass have also been
examined in vivo. Sfrp1/ mice have an increase in trabe-
cular bone, and this increase is more remarkable in the
female mice [30]. The number of osteoblasts and the rate
of bone formation are increased in Sfrp1/ mice due to the
suppression of osteoblast apoptosis. These results suggest
that the canonical Wnt pathway is involved in the prolifera-
tion and differentiation of osteoblasts. Dkk1/ mice are
embryonic lethal due to defects of head induction and limb
formation defects. Dkk1+/ mice have an increased bone
mass due to an increase in bone formation with an increased
number of osteoblasts and increased rate of bone formation
[31]. In contrast, Dkk2/ mice develop osteopenia with anincrease in osteoid matrix [32]. Osteoblasts obtained from
Dkk2/ mice showed mineralization defects in culture.
These results suggest that DKK1 acts as an antagonist, while
DKK2 acts as an agonist in the canonical Wnt pathway in
osteoblast lineage cells. Dkk2/mice also have an increased
number of osteoclasts in vivo (Fig. 3) [33]. The precise role of
DKK2 action in bone resorption is described in the next
section.
The above findings using mutant mice confirm that Wnt
promote osteoblastogenesis and increase bone mass through
the canonical pathway. Recently, it has been shown that
Wnt3a and Wnt7b induce the differentiation of ST2 cells,
mouse bone marrow-derived stromal cells, into osteoblasts
80 Y. Kobayashi et al.via a PKC-dependent mechanism [33]. Wnt3a activates both
the canonical and non-canonical Wnt pathways, while Wnt7b
activates only non-canonical Wnt signaling in ST2 cells. This
suggests that the non-canonical Wnt pathway is also involved
in osteoblast differentiation. This notion is supported by in
vivo and ex vivo analyses of Pkcd/ mice and conditional
knockout mice with osteoblast-specific deletion of Wnt7b
(Wnt7b mutant mice). Both Pkcd/ mice andWnt7b mutant
mice exhibited a deficit in bone formation during embryonic
development [33]. Bone nodule formation is decreased in
osteoblasts in culture obtained from Pkcd/ and Wnt7b
mutant mice. These findings indicate that non-canonical
Wnt signaling is also involved in osteoblastogenesis. The
regulation of bone formation by Wnts seems to be more
complicated than previously believed.
5. Role of Wnt signaling in bone resorption
Osteoclasts are formed in cocultures of osteoblastic stromal
cells and bone marrow cells in the presence of bone resorp-
tion stimulating factors such as 1a,25(OH)2D3 and PTH [3].
Wnt3a strongly inhibits 1a,25(OH)2D3-induced osteoclast for-
mation in cocultures of stromal ST2 cells and bone marrow
cells [34]. However, Wnt3a fails to inhibit RANKL-induced
osteoclast formation in bone marrow macrophage cultures
[34]. These results suggest that the inhibitory effect of Wnt3a
on osteoclast formation is mediated by stromal cells. Glass
et al. [35] developed mice expressing a stabilized form of b-
catenin in osteoblasts (b-catenin mutant mice), and reported
that bone mass was increased, but the number of osteoblasts
and other parameters of osteoblast function remained
unchanged in those mice. Interestingly, the b-catenin mutant
mice developed osteopetrosis with tooth eruption defects
and a decreased number of osteoclasts. Urinary deoxypyr-
idinoline, a marker of osteoclastic bone resorption, was also
decreased in the b-catenin mutant mice. Micro-array analysis
comparing gene expression changes in Lrp5/ mice and b-
catenin mutant mice showed that mRNA expression of OPG, a
decoy receptor of RANKL, is up-regulated in osteoblasts in
those mice [35]. When b-catenin was inactivated selectively
in mature osteoblasts using a1(I) collagen Cremice, the bone
mass was decreased due to the enhancement of bone resorp-
tion [35]. Activation of the canonical Wnt pathway was shown
to stimulate OPG expression in osteoblasts. In addition, the
canonical Wnt pathway suppresses the expression of RANKL in
MC3T3E1 cells and MG-63 cells [36]. These results suggest
that the activation of the canonical Wnt pathway in osteo-
blasts suppresses bone resorption through up-regulation of
OPG expression and down-regulation of RANKL expression
(Fig. 3).
DKK2, an agonist of Wnt signaling, affects bone resorption
as well. Osteoblasts from Dkk2/ mice expressed higher
levels of M-CSF and RANKL than wild-type osteoblasts [32].
The expression of OPG remained unchanged in the mutant
osteoblasts. Osteoclast precursors from Dkk2/ mice in
culture differentiated normally into osteoclasts in the pre-
sence of RANKL and M-CSF. These results suggest that DKK2
acts on osteoblasts and suppresses the expression of RANKL
and M-CSF. It was reported that SFRP1 inhibited the differ-
entiation of macrophages into osteoclasts in the presence of
RANKL and M-CSF [37]. In addition, anti-SFRP1 antibodies
promoted 1a,25(OH)2D3-induced osteoclast formation in thecocultures of osteoblasts and spleen cells. SFRP1 has been
shown to binds to RANKL. RANKL-induced osteoclast forma-
tion was increased in cultures of bone marrow cells derived
from Sfrp1/ mice [30]. These results suggest that SFRP1
inhibits RANKL—RANK interaction. Overall, the canonical Wnt
pathway inhibits osteoclast formation.
Wnt5a has been shown to stimulate the non-canonical Wnt
pathway in the target cells. Recent study has shown that
Wnt5a enhances RANKL-induced osteoclast formation in
mouse bone marrow macrophage cultures [38]. Wnt3a
showed no effect on osteoclast formation in the same culture
system. Mouse bone marrow macrophages expressed Friz-
zleds 2 and 5 and ROR2, the receptor components of Wnt5a.
Knock-down of ROR2 by ROR2-specific short hairpin RNA
abolished the synergistic effect of Wnt5a on osteoclast for-
mation, suggesting that the synergistic effect of Wnt5a on
osteoclast formation is mediated by the Wnt5a—ROR2 axis.
Wnt3a induced the accumulation of b-catenin in bone mar-
row macrophages, but Wnt5a did not. Wnt5a stimulated
phosphorylation of PKC and enhanced RANKL-induced phos-
phorylation of JNK in bone marrow macrophages [38]. These
results suggest that Wnt5a stimulates the non-canonical Wnt
pathway but not the canonical pathway in osteoclast pre-
cursors. It was reported that synovial tissues from rheuma-
toid arthritis (RA) patients produce a large amounts of Wnt5a
[39]. RT-PCR analysis of Wnt expression revealed that osteo-
blasts express higher amounts of Wnt5a than bone marrow
macrophages [38]. These results suggest that Wnt5a secreted
from osteoblasts and RA synovial tissues promotes RANKL-
induced osteoclast formation through ROR2 expressed by
osteoclast precursors in physiological and pathological situa-
tions (Fig. 3).
6. Roles of Wnt signaling in inflammatory
diseases
Expression of several Wnts and Frizzleds has been identified
in RA synovial tissues. The expression levels of Wnt1, Wnt5a,
and frizzled5 are higher in the synovial tissue of RA patients
than in those of osteoarthritis patients [39]. Wnt7b,Wnt4 and
Wnt5a proteins were also detected in synovial tissues of RA
patients [40] and RA model mice [41]. Wnt5a stimulated the
production of pro-inflammatory cytokines such as IL-6 and IL-
8 in synovial cells [42]. Treatment of RA patient-derived
synovial cells with antibodies against frizzled 5, one of the
receptors for Wnt5a, diminished the production of IL-15 and
RANKL [42]. These findings suggest that Wnt5a promotes pro-
inflammatory cytokine production and enhances bone resorp-
tion through the production of RANKL in the pathogenesis of
RA. In addition, as described above, Wnt5a enhanced osteo-
clast formation in mouse bone marrow macrophage cultures.
These results suggest that Wnt5a is involved in bone destruc-
tion in chronic inflammatory diseases such as RA and period-
ontitis. Using human TNFa transgenic mice as an RA model,
DKK1 was shown to play important roles in bone formation.
Treatment of the transgenic mice with anti-DKK1 antibodies
generated osteophytes without any change in the clinical
signs of inflammation [41]. DKK1 has been shown to be
induced by TNFa in inflammatory tissues. These findings
suggest that DKK1 induced by TNFa hampers bone formation
and enhances bone resorption in inflammatory diseases
Wnt signaling in bone 81through blockade of the canonical Wnt pathway. Thus, the
canonical and non-canonical Wnt pathways play important
roles in bone destruction in inflammatory diseases. Molecules
involved in Wnt signaling may be therapeutic targets for the
treatment of patients suffering from RA and periodontitis.
7. Conclusions
Wnts play central roles in the early development of organs and
tissues. In addition, recent studies have established that Wnts
play potential roles in bone remodeling in both physiological
and pathological conditions. The canonical Wnt pathway
enhances differentiation of precursors into osteoblasts. This
signaling pathway also suppresses bone resorption through up-
regulation of OPG expression and down-regulation of RANKL
expression in osteoblasts. Together, these endpoints of the
canonical Wnt pathway lead to an increase in bone mass. In
contrast, the non-canonical Wnt pathway induced by Wnt5a
enhances the formation of osteoclast from the precursor cells.
The activation of this signaling pathway appears to enhance
bone destruction in inflammatory diseases. Thus, Wnt signal-
ing clearly plays multiple important roles in the development
of bone and in the onset and progression of certain bone
diseases. The molecular mechanism of Wnt action in human
bone diseases is not fully understood. Further studies on Wnt
signaling will be needed to establish new therapeutic strate-
gies for the treatment of bone disease.
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